Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810147 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 20
- Study locations
NCT00810147: Completed Phase 2 study of Alzheimers Disease, sponsored by Bristol-Myers Squibb.
NCT00810147 is a Phase 2 study of Alzheimers Disease that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 209 participants, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00810147, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a 12-week wash-out period
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-708163
Study Locations (20)
Florida
- Meridien Research - Brooksville
- Brain Matters Research - Delray Beach
- Md Clinical - Hallandale
- Compass Research, Llc - Orlando
- Miami Research Associates - South Miami
- Usf Suncoast Alzheimer'S And Gerontology Center - Tampa
- Center For Clinical Trials - Venice
California
- Margolin Brain Institute - Fresno
- Collaborative Neuroscience Network, Inc. - Garden Grove
- Pacific Institute For Medical Research, Inc. - Los Angeles
- Mary S. Easton Center - Los Angeles
- Pacific Research Network, Inc - San Diego
- California Neuroscience Research Medical Group, Inc. - Sherman Oaks
Arizona
- 21st Century Neurology - Phoenix
- Banner Alzheimer'S Institute - Phoenix
- Sun Health Research Institue - Sun City
Connecticut
- Yale University School Of Medicine - New Haven
- Comprehensive Psychiatric Care - Norwich
Alabama
- University Of Alabama At Birmingham - Birmingham
Indiana
- Indiana University Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00810147 record still lists
NCT00810147 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00810147 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00810147 about?
NCT00810147 is a clinical study titled "A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a 12-week wash-out period
What is the current status of trial NCT00810147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2009-02. Estimated completion is 2010-06.
What conditions does trial NCT00810147 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00810147?
The interventions under investigation include: Placebo (DRUG), BMS-708163 (DRUG).
Who is sponsoring clinical trial NCT00810147?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00810147 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00810147's enrollment target sits among peer trials
209 57th of 147 higher than 91 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia